Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Although the data are inconclusive about any possible effect on myocardial infarction, rosiglitazone does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucose-lowering drugs. Expand
Randomised controlled trial of structured personal care of type 2 diabetes mellitus
- N. Olivarius, H. Beck-Nielsen, A. Andreasen, M. Hørder, P. A. Pedersen
- BMJ : British Medical Journal
- 27 October 2001
Structured individualised personal care with educational and surveillance support for general practitioners reduced levels of risk factors in type 2 diabetic patients after six years Risk factors were reduced to a level that has been shown to have a beneficial effect on diabetic complications. Expand
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
The interim findings from this ongoing study were inconclusive regarding the effect of rosiglitazone on the overall risk of hospitalization or death from cardiovascular causes. Expand
Heritability of Type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance – a population-based twin study
It is proposed that genetic predisposition is important for the development of abnormal glucose tolerance, and the notion of a multifactorial aetiology of Type II diabetes per se is confirmed. Expand
The LiP (Lifestyle in Pregnancy) Study
- C. Vinter, Dorte M. Jensen, P. Ovesen, H. Beck-Nielsen, J. S. Jørgensen
- Diabetes Care
- 14 November 2011
Lifestyle intervention resulted in a higher adherence to the IOM weight gain recommendations; however, a significant number of women still exceeded the upper threshold. Expand
The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c
- Mette M. Christensen, C. Brasch‐Andersen, +4 authors K. Brøsen
- Pharmacogenetics and genomics
- 1 December 2011
In a large cohort of type 2 diabetics, an enormous (80-fold) variability in trough steady-state metformin plasma concentration is confirmed and OCT1 genotype has a bearing on HbA1c during meetformin treatment. Expand
The new Danish Twin Register: establishment and analysis of twinning rates.
An analysis of trends in the twinning rates for the years 1968-1982 showed that the rate of monozygotic twinning is increasing and the twinned rate of opposite-sex twin pairs is decreasing. Expand
Mitochondrial Respiration Is Decreased in Skeletal Muscle of Patients With Type 2 Diabetes
Evidence is provided for a functional impairment in mitochondrial respiration and increased amount of type 2X fibers in muscle oftype 2 diabetic patients that may contribute to the development of type 1 diabetes in humans with obesity. Expand
Multiple environmental and genetic factors influence skeletal muscle PGC-1alpha and PGC-1beta gene expression in twins.
The finding that the age-dependent decrease in the expression of these key genes regulating oxidative phosphorylation is under genetic control could provide an explanation by which an environmental trigger (age) modifies genetic susceptibility to type 2 diabetes. Expand
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes…
The malignancies rates in these two randomised controlled clinical trials do not support a view that metformin offers any particular protection against malignancy compared with rosiglitazone, but they do not refute the possibility of a difference compared with sulfonylureas. Expand